This publication has been discontinued on September 9, 2011.
Abstract
Stem Cell Research - Market Trends, Investment Trends and Pipeline Analysis
Summary
GBI Research, the leading business intelligence provider, has released its
latest research “Stem Cell Research - Market Trends, Investment Trends
and Pipeline Analysis”. It is an essential source of information and
analysis on global stem cell research and development. This pharmaceutical and
healthcare report identifies the key trends shaping and driving stem cell
research and development. The report analyses investment decisions within the
stem cell research market by providing information on pipelines, federal
spending, investor perspectives, regulatory environment, competitive landscape
and market potential. The study also provides insight on the prevalent
competitive landscape and the emerging players expected to significantly shift
the market positioning. Most importantly, the report provides valuable insight
on the pipeline products within the global stem cell industry.
This report is built using data and information sourced from proprietary
databases, primary and secondary research and in-house analysis by GBI
Research’s team of industry experts.
Scope
The scope of this report includes:
- Unmet needs and opportunity analysis
for therapies that are currently in pipeline.
- Market characterization
including market sizing, technology adoption framework and business models for
the stem cell market.
- A cross-country analysis for regulatory
framework, investments, research clusters and support including the US (United
States), the UK (United Kingdom), Germany, France, Japan, China, India,
Singapore, Canada and Australia
- In-depth information and analysis on the
pipeline products expected to bring a shift in the market positions of the
leading manufacturers.
- Analysis and review of the key events and
milestones that will impact the future of the global stem cell market. Each
trend independently researched to provide qualitative analysis of what the
implications on sectors are, and how companies are responding to these
trends.
- Insightful review of key industry drivers, restraints and
challenges which are likely to impact the global stem cell research and
development in the long run.
- Information on the leading market players
and the prevailing competitive landscape. Key companies covered include Osiris
Therapeutics, Aastrom Biosciences, Cytori Therapeutics, Pluristem Therapeutics
and Geron.
Reasons to buy
The report will enhance your decision making capability. It will allow you
to:
- Develop and design your in-licensing and out-licensing strategies
through a review of pipeline products and technologies and by identifying
companies with the most robust pipelines
- Develop business strategies by
understanding the trends shaping and driving stem cell research and
development.
- Drive revenues by understanding key trends, innovative
products and technologies, market segments and companies likely to impact the
stem cell market in the future
- Formulate effective sales and marketing
strategies by understanding the competitive landscape and by analyzing the
performance of various competitors
- Identify emerging players with
potentially strong product portfolio and create effective counter-strategies
to gain competitive advantage
- Organize your sales and marketing efforts
by identifying the market categories and segments that present maximum
opportunities for consolidations, investments and strategic partnerships
-
What’s the next big thing in the stem cell research and development
landscape? - Identify, understand and capitalize.
Table of Contents
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2
List of Figures 6
2 Introduction 7
2.1 GBI Research Report Guidance
7
3 Market Overview 9
3.1 Stem Cell Research - An Introduction
9
3.2 Types of Stem Cell Research 9
3.3 Unmet Needs 10
3.4
Applications of Stem Cell Research 14
4 Market Characterization 16
4.1
Stem Cell Market - An Introduction 16
4.2 Market Sizing 16
4.3
Therapy cost 18
4.4 Technology Adoption Framework 19
4.5 Types of
Business Models 19
4.6 Market Drivers 21
4.6.1 Supporting Political
Environment on Embryonic Stem Cell Research will Advance the Stem Cell
Industry to Prosper in the United States 21
4.6.2 Limited Availability of
Treatments to Treat Certain Disease Conditions Increases Market Opportunity
for Stem Cell Research 22
4.7 Market Barriers & Challenges 23
4.7.1
Stem Cell Research and Development is an expensive process which requires
considerable funding to be operational. 23
4.7.2 Availability of Adequate
Reimbursements are Unclear and leads to a conundrum 23
4.7.3 Ethical,
legal and social issues persists and acts as a challenge 24
4.7.4
Identifying, recruiting and retaining the best scientific talents is an
intractable process for stem cell research based companies 25
4.8 Stem
Cell Research and Development - Market Trends 25
4.8.1 Booming Stem Cell
Tourism is a Potential Opportunity for Countries to Attract Investments.
25
4.8.2 ASLAP Analysis of Stem Cell Tourism 26
4.8.3 Federal Funding
Support Improves the Stem Cell Research Environment 27
4.8.4 Increasing
Entry of Pharmaceutical Companies Boosts Stem Cell Research & Development
28
4.8.5 PESTLE Analysis 30
4.8.6 SWOT Analysis of Stem Cell Research
& Development 31
4.9 Industry Analysis 33
5 Stem Cell Research and
Development - Pipeline Analysis 35
5.1 Pipeline by Various Phases 35
5.2 Phase III Pipeline Analysis 35
5.3 Phase II Pipeline Analysis 37
5.4 Preclinical and Phase 1 Pipeline 39
6 Stem Cell Research and
Development - Investment Trends 40
6.1 Investor’s Perspective on
Stem Cell Research 40
6.2 NIH spending in Stem Cell Research and
Development is Increasing and is Supportive 42
6.2.1 NIH Spending by
Stem Cell Research Type 43
6.2.2 High Budget Projects Funded by NIH 44
6.3 States Funding on Stem Cell Research in the US is in Reconsideration.
45
6.4 R&D Spending by Stem Cell Research Companies 46
7 Stem Cell
Research and Development - Geographical Trends 47
7.1 Stem Cell Companies
by Geographic Regions 47
7.2 The United States 48
7.3 United Kingdom
49
7.4 China 50
7.5 Netherlands 51
7.6 Singapore 52
7.7 South
Korea 53
7.8 Japan 54
7.9 India 55
7.10 Sweden 56
7.11 Denmark
57
7.12 France 58
7.13 Germany 59
7.14 Israel 60
7.15
Australia 61
7.16 Canada 62
7.17 Czech Republic 63
8 Stem Cell
Research and Development - Mergers and Acquisitions 64
9 Stem Cell
Research and Development - Competitive Structure 65
9.1 Stem Cell
Companies by Therapy Areas 65
9.2 Stem Cell Companies by Stem Cell Types
66
10 Stem Cell Research and Development - Company Profiles 67
10.1
Aastrom Biosciences 67
10.2 Osiris Therapeutics 67
10.3 Bioheart
68
10.4 Aldagen 68
10.5 Mesoblast 69
10.6 Geron 69
10.7
Advanced Cell Technology 70
10.8 Cytori Therapeutics 70
10.9 Pluristem
Therapeutics 71
10.10 Medistem 71
10.11 Neostem 72
11 Stem Cell
Research and Development - Conclusion 73
12 Appendix 74
12.1 Market
Definitions 74
12.2 Key Support Data 74
12.3 Abbreviations 74
12.4
Methodology 74
12.4.1 Coverage 75
12.4.2 Secondary Research 75
12.4.3 Primary Research 76
12.4.4 Expert Panels 76
12.5 Contact Us
76
12.6 Disclaimer 76
1.1 List of Tables
Table 1: Disease
Conditions and Population in US 18
Table 2: Preferred Countries for Stem
Cell Tourism 25
Table 3: Pharmaceutical Companies Partnership Environment
29
Table 4: Phase III Pipeline 35
Table 5: Phase II Pipeline 37
Table 6: Preclinical and Phase 1 Pipelines 39
Table 7: NIH Spending
42
Table 8: Spending of States in US on Stem Cell Research 45
Table 9:
Mergers and Acquisitions in Stem Cell Research 64
Table 10: Aastrom
Biosciences 67
Table 11: Osiris Therapeutics 67
Table 12: BioHeart
68
Table 13: Aldagen 68
Table 14: Mesoblast 69
Table 15: Geron
69
Table 16: Advanced Cell Technology 70
Table 17: Cytori Therapeutics
70
Table 18: Pluristem Therapeutics 71
Table 19: Medistem 71
Table
20: Neostem 72
1.2 List of Figures
Figure 1: Stem Cell Research
and Development Segmentation 9
Figure 2: Stem Cells - Interaction
Framework 11
Figure 3: Cells Models -Present and the Future 12
Figure 4: Unmet Need Vs Time to Market 13
Figure 5: Adult Stem Cells
- Applications 14
Figure 6: Technology Adoption Framework 19
Figure 7: Business Models in Stem Cell Industry 20
Figure 8: Political
Environnent - Impact Analysis 21
Figure 9: Treatment Availability
- Impact Analysis 22
Figure 10: Cost of Research - Impact
Analysis 23
Figure 11: Reimbursements - Impact Analysis 23
Figure 12: Ethical, legal and Social Issues - Impact Analysis 24
Figure 13: Human Resources - Impact Analysis 25
Figure 14: ASLAP
Analysis of Stem Cell Tourism 26
Figure 15: Stem Cell Research- Federal
Funding Trend 27
Figure 16: PESTLE Analysis of Stem Cell Research 30
Figure 17: SWOT Analysis of Stem Cell Research and Development 31
Figure
18: SWOT Analysis of Stem Cell Research and Development - Impact Grid
32
Figure 19: Five Force Analysis 33
Figure 20: Stem Cell Development
Pipeline by Clinical Trial Phase 35
Figure 21: VC’s Perspective on
Stem Cell Research 40
Figure 22: VC’s Perspective on Stem Cell
Research - Impact Analysis 41
Figure 23: NIH Spending by Stem cell
Research Type 43
Figure 24: High Budget Projects Funded by NIH 44
Figure 25: R&D Spending by Public Companies 46
Figure 26: Stem Cell
Companies by Geographic Regions 47
Figure 27: Country Analysis -
United States 48
Figure 28: Country Analysis - United Kingdom 49
Figure 29: Country Analysis - China 50
Figure 30: Country Analysis
- Netherlands 51
Figure 31: Country Analysis - Singapore
52
Figure 32: Country Analysis - South Korea 53
Figure 33:
Country Analysis - Japan 54
Figure 34: Country Analysis -
India 55
Figure 35: Country Analysis - Sweden 56
Figure 36:
Country Analysis - Denmark 57
Figure 37: Country Analysis -
France 58
Figure 38: Country Analysis - Germany 59
Figure 39:
Country Analysis - Israel 60
Figure 40: Country Analysis -
Australia 61
Figure 41: Country Analysis - Canada 62
Figure 42:
Country Analysis - Czech Republic 63
Figure 43: Mergers and
Acquisitions - Year wise Analysis 64
Figure 44: Stem Cell Companies
by Therapy Areas 65
Figure 45: Stem Cell Companies by Stem Cell Types
66
Figure 46: GBI Research Methodology 75
